Viridian Therapeutics, Inc. (VRDN) Stock Price & Analysis

Viridian Therapeutics, Inc. (VRDN) closed at USD 24.27 on Wednesday, October 28, 2026, up 0.75% on the day. The US market is currently closed; this is not a live price.

The prior close was USD 24.09; the Oct 28, 2026 session ranged USD 23.66–24.42 on volume of 1,412,513 shares. Market capitalization is $2.75B, with a 52-week range of USD 13.18–34.29 (NCM). Source: Nexqual, retrieved October 29, 2026 at 07:44 UTC.

Also available as compact Markdown for AI agents: nexqual.com/VRDN.md

Key facts (VRDN)

• Last four reported quarters (through Jun 30, 2026): revenue $71.1M, net income -$387M (-544.1% margin), free cash flow -$335M (SEC filings).
• Insider open-market sales, last ~7 months: 1 Form 4 filings, $348K; 1 not under a Rule 10b5-1 plan ($348K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Insider open-market purchases, last ~7 months: 1 Form 4 filing, $20.0M; 0 by opportunistic insiders, 0 by routine insiders.
• Analysts: Buy (mean 1.82 on a 1–5 scale) (17 analysts), mean target USD 36.2 (range 22–50).
• Total return with dividends: 1Y +5.5% vs S&P 500 +13.6%; 5Y +34.1% vs S&P 500 +79.8%.
• Next earnings: 2026-11-04, EPS estimate USD -1.02, revenue estimate $4.7M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (VRDN)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (VRDN)

P/S 38.7x · EV/Sales 28.3x · P/B 4.2x · FCF yield -12.18% · Earnings yield -14.07% · Net cash $739M · EV $2.01B

Insider sales (SEC Form 4, open-market, last ~7 months) (VRDN)

0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Insider purchases (SEC Form 4, open-market, last ~7 months) (VRDN)

1 purchase, $20.0M. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.

Analysts (VRDN)

Consensus Buy (mean 1.82 on a 1–5 scale), 17 analysts; mean target USD 36.2 (low 22, high 50).

Rating changes, last 120 days:

Total return (dividends reinvested) (VRDN)

VRDN earnings history and stock reaction

EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).

VRDN recent SEC filings (last 120 days)

Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.

VRDN suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 26, 2026.

VRDN company outlook (results filed Aug 6, 2026)

• “FCRN PORTFOLIO • VRDN-008: phase 1 healthy volunteer data expected in 2H 2026 • VRDN-008 phase 1 clinical trial in healthy volunteers is ongoing.”
• “Existing cash and anticipated future commercial revenues from Lumvoa and elegrobart, if approved, are expected to fund Viridian's current business plans through profitability. • R&D Expenses: Research and development expenses were $71.6 million for the three months ended June 30, 2026, compared to $86.6 million for the three months ended June 30, 2025.”

Quoted word-for-word from the SEC 8-K results press release.

VRDN analyst estimates and revisions

VRDN options: expected move

Options price a move of about ±21.1% (±$5.00) by Nov 20, 2026, which includes earnings on Nov 4, 2026. Over the last 8 reports the stock moved ±10.1% on average.

30-day implied volatility 72.5% vs 57.2% realized over the last 30 trading days. Put/call ratio (volume) 0.04. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 29, 2026 at 07:44 UTC)

Technical Analysis (VRDN)

Nexqual's technical model rates VRDN "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 29, 2026 at 07:44 UTC.

Analyst Ratings (VRDN)

Wall Street analysts rate VRDN "Buy" based on 17 analysts, with a mean price target of USD 36.2 (range USD 22–50), per Nexqual as of October 29, 2026 at 07:44 UTC.

Earnings (VRDN)

Recent Earnings History

Source: Nexqual, October 29, 2026 at 07:44 UTC.

Financials & Fundamentals (VRDN)

Source: Nexqual, October 29, 2026 at 07:44 UTC.

Financial Health Score (VRDN)

Nexqual rates Viridian Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 07:44 UTC.

Ownership (VRDN)

Source: Nexqual, October 29, 2026 at 07:44 UTC.

Leadership (VRDN)

Viridian Therapeutics, Inc. is led by Stephen F. Mahoney, CEO, President & Director, per Nexqual as of October 29, 2026 at 07:44 UTC.

Major Backers & Investors (VRDN)

Notable institutional backers of Viridian Therapeutics, Inc. include FMR, LLC, Fidelity, Bellevue Group AG, according to Nexqual as of October 29, 2026 at 07:44 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 29, 2026 at 07:44 UTC.

From Viridian Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• We have an exclusive license to the worldwide rights to develop and commercialize veligrotug for all non-oncology indications that do not use radiopharmaceuticals, including the treatment of patients with TED, from ImmunoGen, Inc. ("ImmunoGen").
• As of January 2026, our in-licensed and owned patent portfolio consists of approximately three U.S. issued patents, approximately twenty-two U.S. pending patent applications, one issued patent in China, and approximately one hundred nineteen patent applications pending in jurisdictions outside of the United States (including approximately twelve pending Patent Cooperation Treaty (PCT) applications) that, in many cases, are counterparts to the foregoing U.S. patents and patent applications.
• The restoration period cannot be longer than five years and the total patent term, including the restoration period, must not exceed 14 years following FDA approval, however there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and if granted, the length of such extensions.
• Our approach leverages proven biology on clinically validated targets and our internal capabilities such as protein and antibody engineering to reduce development risk while striving to address unmet needs for patients including improved clinical outcomes, reduced side effects, improved quality of life, and expanded market access. •Advance our lead programs in thyroid eye disease (TED):

Legal & Regulatory Risks (Item 1A, quoted)

• Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial viability of approved labeling, or result in significant negative consequences following marketing approval, if any.
• Our business operations and market access arrangements will be subject to applicable healthcare regulatory laws, which, if not properly adhered to, could expose us to penalties.
• We and our third-party manufacturers may be impacted by global conflicts, including any potential conflict involving China and Taiwan, and any resulting trade sanctions or regulatory actions.
• Changes in patent laws in the U.S. and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products, and recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 07:44 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt